Serum proPSA as a marker for reducing repeated prostate biopsy numbers

Sema Nur Ayyıldız 1 , Tevfik Noyan 1 , Ali Ayyıldız 2 , Erdal Benli 2 , Abdullah Çırakoğlu 2  and Cemal Ayyıldız 3
  • 1 Ordu University Medical Faculty, Biochemistry Department, Ordu, Turkey
  • 2 Ordu University Medical Faculty, Urology Department, Ordu, Turkey
  • 3 Private Statistician, Samsun, Turkey
Sema Nur Ayyıldız, Tevfik Noyan, Ali Ayyıldız, Erdal Benli, Abdullah Çırakoğlu and Cemal Ayyıldız

Abstract

Introduction:

Prostate specific antigen (PSA) has a lower sensitivity and specifity range of 4–10 ng/mL. We aimed to investigate the effectiveness of pPSA in reducing number of prostate biopsies.

Methods:

This study enrolled 80 patients aged 50 years or older whom had serum total PSA levels between 4 ng/dL and 10 ng/dL. Age, prostate volume, tPSA, fPSA, pPSA, PSA%, pPSA%, t/pPSA, f/pPSA, p/fPSA, p/tPSA, f/p/tPSA, p/f/tPSA, PSAD, fPSA/PSAD, pPSA/PSAD, (Prostate Health Index) PHI, (t/f/pPSA)/tPSA, and PHI2 (New Prostate Health Index) biopsy results were compared between subjects BPH and PCa.

Results:

Out of 80 subjects, 23 (29%) had PCa and 57 (71%) had BPH. Prostate volume was 51.65 mL in PCa and 64.85 mL in non-PCa group (p>0.05). The rate of PCa increased as prostate volume was reduced and age increased. fPSA, PSA%, p/f/tPSA, fPSA/PSAD values were significant in favor of respectively; BPH, BPH, PCa and BPH (p<0.05).

Discussion:

Using prostate health index (PHI) was beneficial for predicting PCa. In addition, using pPSA in formulas such as (PHI2) pPSA/(fPSA*√tPSA), p/f/tPSA, (t/f/pPSA)/tPSA may also be useful. This study suggests that the use of pPSA may have a role in reducing the number of prostate biopsies in differentiating PCa and BPH.

  • 1.

    Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Assoc 1998;279:1542–7.

    • Crossref
    • Export Citation
  • 2.

    Şahin H. Prostat rebiyopsisi: kime, ne zaman, nasıl? Üroonkoloji Bülteni 2012;11:103–7.

  • 3.

    Ismail MT, Gomella LG. Transrectal prostate biopsy. Urol Clin North Am 2013;40:457–72.

    • Crossref
    • PubMed
    • Export Citation
  • 4.

    Lazzeri M, Haese A, Taille A, Redorta JP, McNicholas T, Lughezzani G, et al. Serum isoform [-2] proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. E Urol 2013;63:986–94.

    • Crossref
    • Export Citation
  • 5.

    Ayyıldız SN, Ayyıldız A. PSA, PSA derivates, proPSA and prostate health index in the diagnosis of prostate cancer. Turk J Urol 2014;40:82–8.

    • Crossref
    • Export Citation
  • 6.

    Ataus S. Prostat kanseri dışında PSA yükselmeleri, Prostat Spesifik Antijen. Erözenci A, Ataus S, editors. Ayhan Matbaası, İstanbul, 2003:19–32.

  • 7.

    Catalona W, Partin A, Sanda M, Wei J, Klee G, Bangma C, et al. A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185:1650–5.

    • Crossref
    • PubMed
    • Export Citation
  • 8.

    Loeb S, Sokoll L, Broyles D, Bangma C, vanSchaik R, Klee G, et al. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol 2013;189:1702–6.

    • Crossref
    • PubMed
    • Export Citation
  • 9.

    Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y. The impact of baseline [-2] proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 2014;140:257–63.

    • Crossref
    • PubMed
    • Export Citation
  • 10.

    Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003;170:723–6.

    • Crossref
    • PubMed
    • Export Citation
  • 11.

    Miyakubo M, Ito K, Yamamoto T, Takechi H, Ohi M, Suzuki K. Proprostate specific antigen: its usefulness in the era of multiple core prostate biopsy. Int J Urol 2009;16:561–5.

    • Crossref
    • PubMed
    • Export Citation
  • 12.

    Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004;171:2239–44.

    • Crossref
    • PubMed
    • Export Citation
  • 13.

    Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004;50:1017–25.

    • Crossref
    • PubMed
    • Export Citation
  • 14.

    de Vires SH, Raaijmakers R, Blijenberg BG, Mikolajczyk SD, Rittenhouse HG, Schröder FH. Additional use of [-2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen detected prostate cancer. Urology 2005;65:926–30.

    • Crossref
    • PubMed
    • Export Citation
  • 15.

    Filella X, Gimenez N. Evaluation of [-2] proPSA and prostate health index (phi) for he detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729–39.

  • 16.

    Chiu PK, Lai FM, Teoh JY, Lee WM, Yee CH, Chan ES, et al. Prostate health index and %p2PSA predict aggressive prostate cancer pathology in Chinese patients undergoing radical prostatectomy. Ann Surg Oncol 2016;23:2707–14.

    • Crossref
    • PubMed
    • Export Citation
  • 17.

    Yu GP, Na R, Ye DW, Qi J, Liu F, Chen HT, et al. Performance of the prostate health index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. Asian J Androl 2016;18:1–6.

  • 18.

    Pecoraro V, Roli L, Plebani M, Trenti T. Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review. Clin Chem Lab Med 2016;54:1123–32.

    • PubMed
    • Export Citation
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Turkish Journal of Biochemistry (TJB), official journal of Turkish Biochemical Society, is issued electronically every 2 months. The main aim of the journal is to support the research and publishing culture by ensuring that every published manuscript has an added value and thus providing international acceptance of the “readability” of the manuscripts published in the journal.

Search